HOME >> BIOLOGY >> NEWS
Einstein researchers' prototype vaccine could provide improved protection against tuberculosis

(BRONX, NY) -- Using a novel approach, researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a prototype vaccine against tuberculosis (TB) that works better in animal models than the only TB vaccine now available. In this era of multi-drug resistant TB and growing numbers of people with active TB due to coinfection with HIV, the advance could herald a needed breakthrough against one of the worlds leading killers. Their study appears in the August issue of the Journal of Clinical Investigation.

TB is caused by Mycobacterium tuberculosis, a bacterial species that infects one third of the worlds population (up to 10% of whom will develop active TB) and causes up to three million deaths annually. The only available vaccine--known as Bacille Calmette-Gurin (BCG)is a live, attenuated (weakened) strain of M. bovis, which causes TB in cattle. Despite being the worlds most widely used vaccine, BCG fails to protect adults from TB infection and doesnt reliably stem the reactivation of pulmonary TB (the most common form of the disease) in adults.

Virtually all efforts to develop a better TB vaccine have focused on boosting BCGmodifying it to elicit a stronger immune response in people, says Dr. William Jacobs, Jr., co-senior author of the paper and a Howard Hughes Medical Institute investigator at Einstein as well as professor of microbiology & immunology and molecular genetics. But we feel that tweaking the marginally useful BCG vaccine is the wrong strategy. So weve started with virulent M. tuberculosisthe organism that actually causes TB in humansand are knocking out certain genes to yield a live, attenuated M. tuberculosis strain that still produces a strong immunological response that protects people.

TB bacteria invade human cells and then--successfully evading a persons immune response--lurk inside cells and multiply. A key evasion strategy involves preventing their host cells from undergoing apopto
'"/>

Contact: Larry Katzenstein
lkatzens@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
1-Aug-2007


Page: 1 2 3

Related biology news :

1. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
2. Einstein researchers discover radiation-eating fungi
3. Einsteins Dr. Vern Schramm elected to the National Academy of Sciences
4. Einstein researchers discover how a key dietary vitamin is absorbed
5. NCI funds Einstein and U. Albany NanoCollege to make worlds smallest cancer detection device
6. Team at CNSE and Einstein receive grant to develop worlds smallest cancer detection device
7. Einstein researchers demonstrate a novel approach to treating AIDS
8. Einsteins Dr. E. Richard Stanley receives 2006 E. Donnall Thomas Prize
9. Einstein researchers find key to unlocking worlds deadliest malaria parasite
10. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility
11. Einstein researchers take the pulse of a gene in living cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/15/2018)... ... September 14, 2018 , ... ... campaign will showcase the innovative work being done within rare diseases research, diagnostics, ... for those living with rare diseases. , The print component ...
(Date:9/12/2018)... ... September 11, 2018 , ... ... to introduce the new ChemXP™ line of high performance secondary containment coatings, designed ... developed to provide Tennant Coatings’ elite certified installers with the needed solutions to ...
(Date:9/12/2018)... ... September 12, 2018 , ... Captiva Spine, Inc., which ... has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to ... System. , TowerLOX-EXT MIS Extended Tab Pedicle Screws provide the narrow insertion of ...
Breaking Biology News(10 mins):
(Date:9/12/2018)... ... 2018 , ... Sterlitech Corporation, a global leader in custom ... Fluid Technology Solutions (FTS H2O) to their offering of filtration products. , ... (CTA) material. The highly hydrophilic nature of the CTA FO membranes favors proper ...
(Date:9/7/2018)... ... September 06, 2018 , ... ... neuromuscular disease, has been validated to be as effective as manual pathology. The ... Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology & ...
(Date:8/29/2018)... ... 2018 , ... Nanovis , an innovative and fast-growing ... a $5.5 million funding round managed by Commenda Securities. Key investors include Elevate ... Ventures. , “Our investment in Nanovis is consistent with our mission to support ...
(Date:8/29/2018)... ... August 28, 2018 , ... USDM Life Sciences , ... sciences and healthcare industries, announces that Manu Vohra will deliver a presentation at the ... “How to Implement Box for GxP in 30 Days” , When: Thursday, August ...
Breaking Biology Technology:
Cached News: